Chenyang Li
- Biotechnology top 10%
- Cancer Research and Treatments 6
-
- IL-33, ST2, and ILC Pathways 3
-
- Cancer-related molecular mechanisms research 5
- Cancer Genomics and Diagnostics 4
- Breast Cancer Treatment Studies 3
-
- Cancer Immunotherapy and Biomarkers 4
-
- Nanoplatforms for cancer theranostics 5
-
- RNA modifications and cancer 4
- Cited by
- BiotechnologyImmunologyEndocrinology
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Chenyang Li
51 papers receiving 533 citations
Peers
Comparison fields: 5 of 102
- Biotechnology 64
- Immunology 123
- Endocrinology 22
- Cancer Research 61
- Oncology 103
Countries citing papers authored by Chenyang Li
This map shows the geographic impact of Chenyang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenyang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenyang Li more than expected).
Fields of papers citing papers by Chenyang Li
This network shows the impact of papers produced by Chenyang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenyang Li. The network helps show where Chenyang Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Chenyang Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 1 | |
| 6 | 2025 | 0 | |
| 7 | 2025 | 0 | |
| 8 | 2024 | 4 | |
| 9 | 2024 | 1 | |
| 10 | 2024 | 13 | |
| 11 | 2024 | 3 | |
| 12 | 2024 | 21 | |
| 13 | 2024 | 21 | |
| 14 | 2023 | 9 | |
| 15 | 2023 | 4 | |
| 16 | 2022 | 8 | |
| 17 | 2022 | 3 | |
| 18 | 2021 | 7 | |
| 19 | 2020 | 36 | |
| 20 | 2020 | 36 |
About Chenyang Li
Chenyang Li is a scholar working on Cancer Research, Biotechnology, Immunology, Oncology and Biological Psychiatry, having authored 58 papers that have together received 542 indexed citations. Recurring topics across this work include Cancer Research and Treatments (6 papers), Nanoplatforms for cancer theranostics (5 papers), Cancer-related molecular mechanisms research (5 papers), Cancer Genomics and Diagnostics (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), RNA modifications and cancer (4 papers), IL-33, ST2, and ILC Pathways (3 papers) and Breast Cancer Treatment Studies (3 papers). The work is most often cited by research in Biotechnology (64 citations), Immunology (123 citations), Endocrinology (22 citations), Cancer Research (61 citations) and Oncology (103 citations). Chenyang Li has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Zhendan He, Xun Song, Zichun Hua, Haiqiang Wu, Kai Zheng, Lin Li, Xin Cai, Tianze Zhang, Jiban Kumar Kundu and Jia Zhao. Their work appears in journals such as Cancer Medicine, BMC Nursing, Viruses, Scientific Reports and Acta Pharmaceutica Sinica B.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.